Loading…
NRx Pharmaceuticals, Inc. is projected to rise to $6.27 by 2027, a +46% move from its current price of $4.28. NRXP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.06 | $4.28 | $4.52 | +0.10% |
| May 30 | $3.98 | $4.29 | $4.62 | +0.20% |
| May 31 | $3.92 | $4.29 | $4.70 | +0.30% |
| Jun 1 | $3.87 | $4.30 | $4.78 | +0.39% |
| Jun 2 | $3.82 | $4.30 | $4.84 | +0.49% |
| Jun 3 | $3.78 | $4.31 | $4.90 | +0.59% |
| Jun 4 | $3.75 | $4.31 | $4.96 | +0.69% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.75 | $4.31 | $4.96 | +0.69% |
| Week 2 | $3.56 | $4.34 | $5.29 | +1.38% |
| Week 3 | $3.43 | $4.37 | $5.57 | +2.08% |
| Week 4 | $3.33 | $4.40 | $5.82 | +2.79% |
| Week 5 | $3.24 | $4.43 | $6.06 | +3.50% |
| Week 6 | $3.17 | $4.46 | $6.28 | +4.21% |
| Week 7 | $3.10 | $4.49 | $6.50 | +4.93% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NRx Pharmaceuticals, Inc. is a healthcare company that operates as a clinical-stage biopharmaceutical firm focused on treatments for central nervous system disorders in the United States. Its work covers suicidal depression, PTSD, and schizophrenia through its NRx and Dura segments, with products including NRX-101, NRX-100, and KETAFREE, as well as precision-based interventional psychiatry services.
The company was founded in 2015 and is headquartered in Wilmington, Delaware.
NRx Pharmaceuticals, Inc. (NRXP) trades in the Healthcare sector with a current price of $4.31 and a market capitalization of $156.15M. It holds a rank of 4002 by market cap. The stock sits in a niche of clinical-stage CNS therapies and related services.
The forecasted price path shows meaningful upside over the coming years, with the average price rising across selected horizons and a notable long-term breakout implied by the numbers.
A major floor 60.7% below — a decisive break under it would weaken the trend.
The nearest floor, 41.4% below — buyers have tended to step in here.
Price is pressing into resistance (0.7% away) — a breakout level to watch.
A major ceiling 28.5% above — clearing it would confirm fresh momentum.
Key NRXP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NRXP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.57 | Buy | $3.77 | Buy |
| MA 10 | $3.34 | Buy | $3.48 | Buy |
| MA 20 | $3.17 | Buy | $3.23 | Buy |
| MA 50 | $2.70 | Buy | $2.83 | Buy |
| MA 100 | $2.35 | Buy | $2.60 | Buy |
| MA 200 | $2.53 | Buy | $2.54 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 77.57 | Sell |
| Stoch RSI (14) | 96.04 | Sell |
| CCI (20) | 300.76 | Buy |
| Williams %R (14) | -2.01 | Info |
| MACD (12,26,9) | 0.10 | Buy |
| ROC (12) | 38.96 | Buy |
| Bollinger %B (20,2) | 1.21 | Sell |
| Stochastic %K (14) | 97.99 | Sell |
| TRIX (15) | 0.99 | Buy |
| Awesome (5,34) | 0.60 | Buy |
| Ultimate (7,14,28) | 77.28 | Sell |
| Momentum (10) | 1.41 | Buy |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 3.98 | Buy |
| ADX (14) | 27.00 | Buy |
| ATR (14) | 0.16 | Info |
The near-term technical picture shows bullish momentum with an overbought read on the RSI. RSI14 is 80, and the stock trades above its short- and medium-term moving averages, with SMA50 at $2.65 and SMA200 at $2.53.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.68 | $4.28 | $6.94 | 0% | Neutral | |
| $4.52 | $6.27 | $9.41 | +46% | Bullish | |
| $4.10 | $6.02 | $9.61 | +41% | Bullish | |
| $4.56 | $7.05 | $11.79 | +65% | Bullish | |
| $4.40 | $7.14 | $12.40 | +67% | Bullish | |
| $4.77 | $8.07 | $14.51 | +89% | Bullish | |
| $7.42 | $13.10 | $24.26 | +206% | Bullish | |
| $7.62 | $13.98 | $26.60 | +227% | Bullish | |
| $6.84 | $13.05 | $25.45 | +205% | Bullish | |
| $7.00 | $13.88 | $27.70 | +224% | Bullish | |
| $11.31 | $25.14 | $55.07 | +487% | Bullish | |
| $25.67 | $57.05 | $131.23 | +12.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.68 | $4.28 | $5.15 | +0.00% |
| June 2026 | $3.89 | $4.66 | $5.79 | +8.94% |
| July 2026 | $3.84 | $4.68 | $5.96 | +0.40% |
| August 2026 | $3.95 | $4.88 | $6.34 | +4.27% |
| September 2026 | $4.19 | $5.23 | $6.89 | +7.15% |
| October 2026 | $4.11 | $5.19 | $6.93 | -0.84% |
| November 2026 | $3.90 | $4.96 | $6.71 | -4.41% |
| December 2026 | $3.95 | $5.07 | $6.94 | +2.31% |
Click any year to see its month-by-month NRXP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect NRXP to range from $1.68 to $6.94 through 2026. The $4.28 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The NRXP price prediction for 2027 points to an average of $6.27 (low $4.52, high $9.41) — a potential gain of +46% on today's $4.28. Momentum favours further upside here.
In 2028, NRXP is projected to trade between $4.10 and $9.61, averaging $6.02 — a potential gain of +41% from today's $4.28. That is -4% versus the projected 2027 average. Buyers look set to stay in control over this stretch.
NRx Pharmaceuticals, Inc.'s 2029 outlook centres on $7.05, within a $4.56 to $11.79 range. That is up +17% on the projected 2028 average. That marks a +65% change versus current levels. Momentum favours further upside here.
By 2030, NRXP could reach as high as $12.40, with a base case around $7.14 and support toward $4.40 — roughly +67% from $4.28. Buyers look set to stay in control over this stretch.
Expect NRXP to range from $4.77 to $14.51 through 2031. The $8.07 average target implies a +89% move from current prices. That is up +13% on the projected 2030 average. Momentum favours further upside here.
The NRXP price prediction for 2032 points to an average of $13.10 (low $7.42, high $24.26) — a potential gain of +206% on today's $4.28. Buyers look set to stay in control over this stretch.
In 2033, NRXP is projected to trade between $7.62 and $26.60, averaging $13.98 — a potential gain of +227% from today's $4.28. That is up +7% on the projected 2032 average. Momentum favours further upside here.
NRx Pharmaceuticals, Inc.'s 2034 outlook centres on $13.05, within a $6.84 to $25.45 range. That is -7% versus the projected 2033 average. That marks a +205% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, NRXP could reach as high as $27.70, with a base case around $13.88 and support toward $7.00 — roughly +224% from $4.28. Momentum favours further upside here.
Expect NRXP to range from $11.31 to $55.07 through 2040. The $25.14 average target implies a +487% move from current prices. That is up +81% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The NRXP price prediction for 2050 points to an average of $57.05 (low $25.67, high $131.23) — a potential gain of +12.3x on today's $4.28. Momentum favours further upside here.
Investing $1,000 in NRXP today (≈ 233.64486 NRXP) could be worth
$13,330.52
+$12,330.52 (+1233%) by 2050 · US Dollar
Based on the average projected NRXP price of $57.05 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NRXPwould be worth at today's price.
$1,000 invested in NRXP on May 27, 2025 (≈ 387.596911 NRXP) would be worth
$1,658.91
+$658.91 (+65.9%) today · 1.66× · US Dollar
Based on a NRXP entry price of $2.58 vs. today's $4.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.97 | $1,441.08 | +44.1% |
| 1 month ago | $3.03 | $1,412.54 | +41.3% |
| 3 months ago | $1.93 | $2,217.62 | +121.8% |
| 6 months ago | $2.45 | $1,746.94 | +74.7% |
| 1 year ago | $2.58 | $1,658.91 | +65.9% |
| All time (5.0y) ago | $217.8 | $19.65 | -98.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NRXP forecast.
Our base-case forecast reaches $8.60 around 2032.
Implied market cap at $8.60: $311.57M
Looking out through 2030 and beyond, the multi-year forecast points to substantial upside. The 2030 average price is $7.16 with a minimum of $4.40 and a maximum of $12.48, and a projected ROI of 66.1% with bullish sentiment. By 2040 the average is forecast at $25.57 (min $11.51, max $56.25) and ROI of 493.3%.
By 2050 the average is forecast at $58.43 (min $26.29, max $134.39) and ROI of 1255.7%, with sentiment remaining bullish across these horizons.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $7.16, with a min of $4.40 and a max of $12.48, and an estimated ROI of 66.1%, with bullish sentiment.
The forecast indicates bullish sentiment from 2027 onward, with notable upside by 2030 ($7.16 avg) and a long-run average of $58.43 by 2050, corresponding to an ROI of 1255.7%. These are estimates, not guarantees.
Current price is $4.31 and market cap is $156.15M.
RSI14 is 80, indicating strong momentum. SMA50 is $2.65 and SMA200 is $2.53, with a 30-day range of $3.01 to $6.18 and a support level at $2.50 and a resistance at $4.31.
The 2040 forecast shows an average price of $25.57, a min of $11.51, a max of $56.25, and an ROI of 493.3%, with bullish sentiment.
NRx Pharmaceuticals, Inc. Community Discussion
0Share your NRx Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.